---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000112"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:35:42.763682+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience hires former GW Pharma USA President Julian Gangolli as Strategic Advisor

## Summary
- Julian Gangolli, former President of GW Pharmaceuticals USA, appointed as Strategic Advisor.
- He oversaw FDA approval of Epidiolex, the first pure CBD drug, leading to GW's $7.2B acquisition by Jazz.
- Previously a senior Allergan executive; part of management that sold Allergan to Actavis in 2015.
- Granted 5,000 stock options at $2.73 per share, exercisable for 5 years.

## SEC filing metadata
- accession: 0001640334-23-000112
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000112/0001640334-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000112/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000112
- JSON: https://secwatch.observer/filing/0001640334-23-000112.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.